ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial

Can Glycine + Amino Acids Be the Secret to Deep, Rejuvenating Sleep?

Exploring the association between Morgellons disease and Lyme disease: identification of Borrelia bu...

Lyme Disease Activists Take Fight to Washington D.C.

New Envita Study Shows Chronic Lyme Disease "Fools" Immune System, Resistant to Antibiotics

Safely Burn Away Body Fat

Omega-3 fatty acids boost B vitamin brain benefit

Substantial health threat: Never-before-seen tick-borne disease

Lyme Advocates Call on IDSA to Focus on Patient Care Instead of Attacking Those in Distress

Trigger identified that likely unleashes autoimmune disease

 
Print Page
Email Article

Long-Term Effects of Savella for Fibromyalgia Evaluated

  [ 6 votes ]   [ Discuss This Article ]
www.ProHealth.com • March 4, 2013


Article:

A 3-Year, Open-Label, Flexible-Dosing Study of Milnacipran for the Treatment of Fibromyalgia.
– Source: The Clinical Journal of Pain, February 26, 2013

By L.M. Arnold, R.H. Palmer and Y. Ma

Abstract:

OBJECTIVES: To evaluate the effects of long-term milnacipran [brand name Savella] treatment in fibromyalgia patients.

METHODS:
Patients completing a previous milnacipran study were eligible to participate in this long-term (up to 3.25 y), open-label study. After washout, dose escalation, and 8 weeks of stable-dose treatment (100 mg/d), patients received flexible doses of milnacipran (50 to 200 mg/d) for the remainder of the study.

Safety evaluations included adverse events and vital signs. Clinical measures included weekly recall pain [visual analog scale (VAS)], Patient Global Disease Status (PGDS), and the Short Form-36 Health Survey [SF-36, including the Physical Component Summary (PCS) and Mental Component Summary scores]. Cohort analyses were conducted to assess the effects of milnacipran over varying periods of time.

RESULTS: Of 1227 patients entering the study, 585 (47.7%) were classified as completers, including 379 (30.9%) patients who were currently enrolled when the study was administratively terminated. Mean duration of treatment was 19 months, with 206 patients reaching the final visit and receiving 36 to 38 months of study treatment.

  • The percentage of patients with ?1 treatment-emergent adverse event was 88.3%, with nausea (25.9%) and headache (13.4%) being the most common events.

  • Discontinuations due to adverse events occurred in 20.9% of patients.

  • Potentially clinically significant increases in blood pressure or heart rate occurred in ?1.1% of patients.

  • Mean improvement from baseline in weekly recall VAS pain was 17.6; improvements in global status (PGDS) and physical functioning (SF-36 PCS) were also observed.

  • In all patient cohorts, these improvements were observed by month 3 and remained relatively constant over time.

  • At final study visit in the 3-year cohort, 70.3% of patients rated their overall fibromyalgia as "much improved" or "very much improved."

DISCUSSION: No new safety concerns were identified in this long-term study. Sustained symptom improvements were found in fibromyalgia patients who received up to 3.25 years of milnacipran treatment.


Source: The Clinical Journal of Pain, February 26, 2013. By L.M. Arnols, R.H. Palmer and Y. Ma. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH; Forest Research Institute Inc., Jersey City, NJ.




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Vitamins and Supplements

Featured Products

Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Vitamin E: Super Antioxidant We Only Thought We Knew Vitamin E: Super Antioxidant We Only Thought We Knew
Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance Front Line Defense Against Colds & Flu - Support for Healthy Immune System Balance
Health Benefits Are Brewing in Green Tea Health Benefits Are Brewing in Green Tea
Fighting Fatigue with Ground-breaking French Oak Wood Extract Fighting Fatigue with Ground-breaking French Oak Wood Extract
Block Acid Reflux to Prevent Esophageal Problems! Block Acid Reflux to Prevent Esophageal Problems!

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing